SCHEMBL4119232

SCHEMBL4119232

Cc1ccc(CN(CCNC(=O)Nc2cccc(Cl)c2)C(=O)Nc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 3/20 0.50
▸ MEN1 O00255 5/20 0.49
▸ KMT2A Q03164 5/20 0.49
▸ LMNA P02545 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ CYP1A2 P05177 2/20 0.49
▸ CYP3A4 P08684 2/20 0.49
▸ CYP2D6 P10635 2/20 0.49
▸ CYP2C9 P11712 2/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ MAPT P10636 4/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ HTT P42858 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ EPHX1 P07099 3/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ MTOR P42345 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4114216 0.90 MEN1 (0.55) CNR1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL4117599 0.86 CNR1 (0.67) CNR1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4113873 0.86 CNR1 (0.67) CNR1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4108817 0.85 MEN1 (0.50) CNR1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL4106239 0.82 MCHR1 (0.52) CNR1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4124108 0.81 MTOR (0.61) CNR1MEN1KMT2ACYP1A2CYP2C9
SCHEMBL5705945 0.81 MEN1 (0.47) CNR1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4118998 0.81 CNR1 (0.61) CNR1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4114482 0.80 EPHX1 (0.51) CNR1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4124705 0.80 EPHX1 (0.51) CNR1MEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS CNR1 3201/4885MEN1 4167/4885KMT2A 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback